TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35098674
Drug: LCL161 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCL161 monotherapy (1200 mg)
Study: 35098674
Drug: LCL161 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCL161 plus paclitaxel (80 mg/m2)
Study: 35098674
Drug: LCL161 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCL161 monotherapy
Study: 32563598
Drug: Post-discharge oral
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-discharge oral nutritional supplements (ONS) with dietary advice
Study: 33041014
Drug: Manual adjustment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual adjustment of norepinephrine infusion (Control)
Study: 33205662
Drug: Durable Polymer
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durable Polymer Drug-Eluting Stent (DP-DES)
Study: 33205662
Drug: Biodegradable Polymer
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biodegradable Polymer Drug-Eluting Stent (BP-DES)
Study: 32002556
Drug: High-dose radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose radiation (64.8 Gy in 36 fractions)
Study: 32002556
Drug: Low-dose radiation
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose radiation (50.4 Gy in 28 fractions)
Study: 36164038
Drug: R-CHOP +
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP + tafasitamab (12 mg/kg intravenously, Days 1, 8, and 15) + LEN (25 mg orally, Days 1-10)
Study: 33792210
Drug: Non-surgical periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical periodontal treatment (oral hygiene instructions, scaling and root planing)
Study: 34015014
Drug: TaurolockU (taurolidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: TaurolockU (taurolidine heparin locks twice a week combined with taurolidine urokinase locks once a week)
Study: 34015014
Drug: Control (taurolidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (taurolidine heparin locks thrice weekly)
Study: 34172071
Drug: Inspiratory and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory and expiratory respiratory muscle training (IEMT) for 8 weeks, consisting of 5 sets of 10 repetitions, three times a day, with increasing training loads weekly
Study: 32708555
Drug: Caffeine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (6 mg·kg−1) for 4 days, acute intake on day 5
Study: 33484864
Drug: Omadacycline 100
Normalized name: omadacycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omadacycline 100 mg intravenously (every 12 h for two doses, then every 24 h) with optional transition to 300 mg orally after 3 days
Study: 33484864
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg intravenously (every 24 h) with optional transition to 400 mg orally after 3 days
Study: 33420673
Drug: Continuous Energy
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Energy Restriction (CER) - average daily energy deficit of 500 kcal
Study: 35914511
Drug: Aspirin +
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin + Ticagrelor
Study: 36352445
Drug: Tablet-based video
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based video game stimulating cognitive and socio-emotional skills
Study: 36352445
Drug: Tablet-based game
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet-based game where students draw and paint (control)
Study: 33228739
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 2 mL/kg of 20% intralipid before aortic cross-unclamping
Study: 34154367
Drug: omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: omega-3 fatty acids (4 g daily)
Study: 35614404
Drug: Home‐Based Multimodality
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home‐Based Multimodality Functional Recovery and Metabolic Health Enhancement Program (FES‐LC plus AE and testosterone therapy)
Study: 35614404
Drug: FES‐LC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: FES‐LC plus AE and placebo injections
Study: 34845002
Drug: Erenumab 140
Normalized name: Erenumab 140 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erenumab 140 mg monthly
Study: 32980696
Drug: combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of treatment protocol of Group A and Group B
Study: 35157781
Drug: Levetiracetam granules
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam granules (500 mg)
Study: 35157781
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution of levetiracetam
Study: 34506883
Drug: Dietary dandelion
Normalized name: DANDELION
DrugBank: Taraxacum officinale pollen (DB10755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary dandelion flower extract (DFE) at 3 g/kg
Study: 34506883
Drug: Dietary dandelion
Normalized name: DANDELION
DrugBank: Taraxacum officinale pollen (DB10755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary dandelion flower extract (DFE) at 2 and 3 g/kg
Study: 34506883
Drug: Dietary dandelion
Normalized name: DANDELION
DrugBank: Taraxacum officinale pollen (DB10755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary dandelion flower extract (DFE) at 3 and 4 g/kg
Study: 34506883
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 g/kg DFE)
Study: 33836265
Drug: On-treatment ctDNA
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On-treatment ctDNA increase
Study: 35151715
Drug: Stereotactic ablative
Normalized name: ABL
DrugBank: Lauric acid (DB03017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic ablative radiotherapy (SABR) - 26 Gy in 2 weekly fractions
Study: 35151715
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose rate (HDR) brachytherapy - 27 Gy in 2 weekly fractions
Study: 34534410
Drug: LYR-210 (2500
Approvals — FDA: no, EMA: no, PMDA: no
Description: LYR-210 (2500 ?g)
Study: 34534410
Drug: LYR-210 (7500
Approvals — FDA: no, EMA: no, PMDA: no
Description: LYR-210 (7500 ?g)
Study: 36070357
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A (BoNT‐A) injection
Study: 32236715
Drug: Glenohumeral injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glenohumeral injection of triamcinolone 8 weeks postoperatively
Study: 32236715
Drug: No injection
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No injection postoperatively
Study: 32186028
Drug: TwHF cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: TwHF cream
Study: 35747933
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of carbohydrate (30g) and protein (15g + 15g)
Study: 34352138
Drug: Zuranolone 30
Normalized name: zuranolone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zuranolone 30 mg
Study: 36026800
Drug: ABP‐051 stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABP‐051 stimulation therapy
Study: 34290862
Drug: Sublingual CoQ10
Normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual CoQ10 (400 mg/d)
Study: 32170665
Drug: OnabotulinumtoxinA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: OnabotulinumtoxinA with antithrombotic therapy
Study: 32170665
Drug: OnabotulinumtoxinA without
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: OnabotulinumtoxinA without antithrombotic therapy
Study: 32170665
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with antithrombotic therapy
Study: 32170665
Drug: Placebo without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo without antithrombotic therapy
Study: 32503946
Drug: ipilimumab 3
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ipilimumab 3 mg/kg
Study: 32503946
Drug: ipilimumab 10
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ipilimumab 10 mg/kg (subgroup with asymptomatic brain metastasis)
Study: 32503946
Drug: ipilimumab 3
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ipilimumab 3 mg/kg (subgroup with asymptomatic brain metastasis)
Study: 32503946
Drug: ipilimumab 10
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ipilimumab 10 mg/kg (wild-type BRAF tumors)
Study: 32503946
Drug: ipilimumab 3
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ipilimumab 3 mg/kg (wild-type BRAF tumors)
Study: 32503946
Drug: ipilimumab 10
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ipilimumab 10 mg/kg (mutant BRAF tumors)
Study: 32503946
Drug: ipilimumab 3
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ipilimumab 3 mg/kg (mutant BRAF tumors)
Study: 36432453
Drug: Discontinue central
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinue central access at an enteral feeding volume of 100 mL/kg/day
Study: 36432453
Drug: Standard discontinuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard discontinuation at an enteral feeding volume of 140 mL/kg/day
Study: 33955599
Drug: Enzalutamide plus
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide plus androgen deprivation therapy
Study: 34400339
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (NO) at 160 ppm for 30 min twice daily
Study: 35144945
Drug: Fresh frozen
Normalized name: Fresh frozen plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh frozen plasma (FFP) (10 mL/kg)
Study: 34363942
Drug: Discontinuing antibiotic
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuing antibiotic therapy
Study: 34363942
Drug: Usual strategy
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual strategy of continuing antibiotic treatment
Study: 38088558
Drug: Ziltivekimab 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziltivekimab 7.5 mg
Study: 38088558
Drug: Ziltivekimab 15
Normalized name: Ziltivekimab
DrugBank: Ziltivekimab (DB18836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziltivekimab 15 mg
Study: 38088558
Drug: Ziltivekimab 30
Normalized name: Ziltivekimab
DrugBank: Ziltivekimab (DB18836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziltivekimab 30 mg
Study: 33739852
Drug: Intensified pegaspargase
Normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensified pegaspargase (four additional doses at 3-week intervals during consolidation and interim maintenance)
Study: 33739852
Drug: Standard COG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard COG low-intensity therapy (including two pegaspargase doses during induction and delayed intensification)
Study: 33739852
Drug: Low-risk patients
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-risk patients (with favorable cytogenetics) compared to standard-risk patients (with identical therapy but without favorable or unfavorable cytogenetics)
Study: 33739852
Drug: Overall survival
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall survival (OS) for standard COG therapy
Study: 36334430
Drug: Chemically protected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemically protected sodium butyrate (CSB) 1,000 mg/kg
Study: 36334430
Drug: Antibiotics (enramycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (enramycin 8 mg/kg and aureomycin 100 mg/kg)
Study: 32699231
Drug: placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo + LSD (100 µg)
Study: 32699231
Drug: 5-HT2A receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-HT2A receptor antagonist ketanserin (40 mg) + LSD (100 µg)
Study: 36071112
Drug: Citalopram (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (8 mg)
Study: 37902943
Drug: IA 40
Normalized name: DROXIA 400mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: IA 40 mg TCA followed by IA 0.07 mg LOR
Study: 37902943
Drug: IA 0.07
Normalized name: TRICHOTHECIUM ROSEUM 0.071 g in 20 mL / PASSALORA FULVA 0.071 g in 20 mL / COCHLIOBOLUS SPICIFER 0.071 g in 20 mL / MYROTHECIUM VERRUCARIA 0.071 g in 20 mL / TRICHOPHYTON SCHOENLEINII 0.071 g in 20 mL / Mycogone nigra 0.071 g in 20 mL / NEUROSPORA CRASSA 0.071 g in 20 mL / KHUSKIA ORYZAE 0.071 g in 20 mL / PAECILOMYCES VARIOTII 0.072 g in 20 mL / MICROASCUS BREVICAULIS 0.072 g in 20 mL / HELMINTHOSPORIUM SOLANI 0.072 g in 20 mL / PLEOSPORA TARDA 0.072 g in 20 mL / STREPTOMYCES GRISEUS 0.072 g in 20 mL / TRICHODERMA VIRIDE 0.072 g in 20 mL PERCUTANEOUS INJECTION, SOLUTION [RINKEL MOLD MIX B]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IA 0.07 mg LOR followed by IA 40 mg TCA
Study: 32895744
Drug: Nebulised saccharin
Normalized name: Saccharin
DrugBank: Saccharin (DB12418)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised saccharin solution
Study: 34184798
Drug: Depot buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depot buprenorphine (CAM2038 weekly for 4 weeks then monthly)
Study: 34184798
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral methadone
Study: 35769196
Drug: Date seed
Normalized name: DATE SEED EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Date seed powder (26 g/d)
Study: 35230053
Drug: High-Dose Pindolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Dose Pindolol
Study: 36169433
Drug: Methylphenidate treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate treatment (Group B)
Study: 32530765
Drug: Boost radiotherapy
Normalized name: BOOST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boost radiotherapy (36 Gy total dose) after single or tandem autologous stem-cell transplantation
Study: 32530765
Drug: Single SCT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single SCT with boost radiotherapy (36 Gy total dose) for incomplete resection
Study: 33529381
Drug: Flapless administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flapless administration of enamel matrix derivative (EMD) as adjunct to re‐instrumentation
Study: 33529381
Drug: Re‐instrumentation without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Re‐instrumentation without adjunctive EMD (control)
Study: 32150296
Drug: Maximum tolerated
Normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maximum tolerated dose combinations from the first stage of the trial
Study: 32150296
Drug: Adaptive randomization
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptive randomization of patients to dose combinations
Study: 36498561
Drug: Platelet-Rich Plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-Rich Plasma (PRP) treatment
Study: 36043781
Drug: Tadalafil (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (20 mg single dose)
Study: 39495582
Drug: P2Y12 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: P2Y12 inhibitors
Study: 33966361
Drug: Liposomal Glutathione
Normalized name: Liposomal glutathione
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal Glutathione (L-GSH)
Study: 33966361
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro Everolimus treatment
Study: 33966361
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of L-GSH and Everolimus
Study: 616117489
Drug: Lomerizine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomerizine (10 mg per day)
Study: 32989916
Drug: Tertiary care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tertiary care multimodal treatment program
Study: 36109819
Drug: Subcutaneous tunnelling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous tunnelling for PICC placement
Study: 34335943
Drug: Cetuximab plus
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab plus chemotherapy (arm A)
Study: 34335943
Drug: Bevacizumab plus
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab plus chemotherapy (arm B)
Study: 32570059
Drug: Laser group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser group (LG) - photobiomodulation (PBM) using a diode laser (660 nm, 10 J/cm2, 0.28 J per point, 40 mW for intra-oral; 810 nm, 25 J/cm2, 0.7 J per point, 40 mW for extra-oral) applied three times a week during radiotherapy.
Study: 32570059
Drug: Sham group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham group (SG) - sham treatment with the instrument tip sealed to prevent light passage.
Study: 35051162
Drug: Ultrasound-guided partial
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided partial release of the transverse carpal ligament using an 18-G needle
Study: 33295133
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: One dose (1 g) of IV‐TXA before skin incision + one dose (1.5 g) of IA‐TXA + single dose of IV‐TXA (1 g) for 3 h
Study: 33295133
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: Two doses of IV‐TXA (1 g) for 3 and 6 h
Study: 33295133
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: Three doses of IV‐TXA (1 g) for 3, 6, and 12 h
Study: 35854762
Drug: Metformin combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin combined with medroxyprogesterone acetate
Study: 33765691
Drug: Endothelin receptor
Normalized name: Endothelin receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endothelin receptor antagonists (ERAs)
Study: 33960725
Drug: GLPG1205 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG1205 10 to 800 mg (single doses)
Study: 33960725
Drug: GLPG1205 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG1205 50 mg (once daily for 14 days)
Study: 33960725
Drug: GLPG1205 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG1205 250 mg loading dose followed by 50 mg once daily for 13 days (open-label part)
Study: 32386000
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg orally every night for 4 weeks
Study: 32386000
Drug: Combined group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined group with atorvastatin and subcutaneous injection of 140 mg evolocumab every 2 weeks for 4 weeks
Study: 33050910
Drug: SRT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRT with concurrent systemic therapies (ST) including chemotherapy, immunotherapy, targeted therapy, and hormonotherapy.
Study: 33050910
Drug: SRT alone
Normalized name: SRT-1720
DrugBank: SRT-1720 (DB17057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRT alone without concurrent ST.
Study: 35884990
Drug: oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebo
Study: 33782086
Drug: Nutritional formulation
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional formulation containing myo-inositol, probiotics, and multiple micronutrients (intervention)
Study: 32169689
Drug: Continued escitalopram
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued escitalopram treatment
Study: 35675076
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of atogepant
Study: 35675076
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of atogepant
Study: 35675076
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of atogepant
Study: 35274326
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg plus standard therapy (hydroxychloroquine + Kaletra®)
Study: 35274326
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (hydroxychloroquine + Kaletra®)
Study: 37087308
Drug: Machine learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine learning (ML) algorithm
Study: 33066811
Drug: Music-based synchronous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music-based synchronous finger tapping (SFT) intervention for 25 minutes daily for 8 weeks
Study: 34895700
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of relugolix (REL) orally once a day for 24 weeks
Study: 34895700
Drug: 3.75 or
Normalized name: Zileze 3.75 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 or 1.88 mg of leuprorelin (LEU) subcutaneously every 4 weeks for 24 weeks
Study: 34895700
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of relugolix (REL)
Study: 34895700
Drug: 3.75 or
Normalized name: Zileze 3.75 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 or 1.88 mg of leuprorelin (LEU)
Study: 38752352
Drug: Sildenafil 20
Normalized name: sildenafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 20 mg TID
Study: 38752352
Drug: Sildenafil 5
Normalized name: sildenafil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 5 mg TID